Literature DB >> 1336344

In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

K C Lamp1, M J Rybak, E M Bailey, G W Kaatz.   

Abstract

Clinical trials with daptomycin were halted in December 1990 because of treatment failures including two resistant Staphylococcus aureus strains. High protein binding of daptomycin (> 90%) and the lower-than-expected concentrations in serum with the dosage regimen of 3 mg/kg of body weight every 12 h may have contributed to these failures. To evaluate the effect that higher concentrations would have on bactericidal activity measured by time-kill curves, peak and trough concentrations were estimated for dosage regimens of 3, 5, and 10 mg/kg every 12 h. MICs, MBCs, and killing curves for daptomycin and vancomycin were performed by using the estimated concentrations with four S. aureus strains obtained from patients who failed daptomycin therapy for endocarditis. MICs and MBCs of daptomycin demonstrated a greater inoculum effect than those of vancomycin; MICs and MBCs of daptomycin increased three- to fourfold, but those of vancomycin increased only one- to twofold when the inoculum was increased from 5 x 10(5) to 5 x 10(7) CFU/ml. No pH-dependent effect on MICs or MBCs was seen. Strenuous experimental conditions were chosen: high inoculums (5 x 10(7) CFU/ml), extremes of pH (6.4, 7.4, and 8), and stationary and exponentially growing organisms; and all experiments completed in the presence of pooled human serum. Daptomycin exhibited concentration-dependent killing and statistically faster kill rates than vancomycin against stationary- or exponential-growth-phase organisms. A pH-dependent decrease in activity with daptomycin was also demonstrated. Daptomycin and vancomycin produced higher kill rates against exponentially growing organisms. A pH-dependent decrease in activity with daptomycin was also demonstrated. Daptomycin and vancomycin produced higher kill rates against exponentially growing organisms. The results indicate that the use of higher dosage regimens with compounds similar to daptomycin may be capable of overcoming the effects of pH, high inoculum, and protein binding.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336344      PMCID: PMC245533          DOI: 10.1128/AAC.36.12.2709

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032.

Authors:  N E Allen; J N Hobbs; W E Alborn
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria.

Authors:  R H Eng; F T Padberg; S M Smith; E N Tan; C E Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

3.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

4.  Inhibition of membrane potential-dependent amino acid transport by daptomycin.

Authors:  N E Allen; W E Alborn; J N Hobbs
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

5.  Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests.

Authors:  L B Reller; C W Stratton
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

6.  Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.

Authors:  D E Low; A McGeer; R Poon
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  In vitro activities of daptomycin and other antimicrobial agents against vancomycin-resistant gram-positive bacteria.

Authors:  L de la Maza; K L Ruoff; M J Ferraro
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

8.  Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus.

Authors:  J P Flandrois; G Fardel; G Carret
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

9.  Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; V N Reddy; E M Bailey; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

View more
  46 in total

1.  Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors:  Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

Review 2.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.

Authors:  Ad C Fluit; Franz-Josef Schmitz; Jan Verhoef; Dana Milatovic
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  Impact of Bacterial Membrane Fatty Acid Composition on the Failure of Daptomycin To Kill Staphylococcus aureus.

Authors:  Rym Boudjemaa; Clément Cabriel; Florence Dubois-Brissonnet; Nicolas Bourg; Guillaume Dupuis; Alexandra Gruss; Sandrine Lévêque-Fort; Romain Briandet; Marie-Pierre Fontaine-Aupart; Karine Steenkeste
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

5.  Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Brian T Tsuji; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Pharmacodynamics of ClpP-Activating Antibiotic Combinations against Gram-Positive Pathogens.

Authors:  Nader Mroue; Anu Arya; Autumn Brown Gandt; Cameron Russell; Angel Han; Ekaterina Gavrish; Michael LaFleur
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

Review 7.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

8.  In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.

Authors:  Amira A Bhalodi; Mao Hagihara; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

9.  Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.

Authors:  Philippe Cottagnoud; Marc Pfister; Fernando Acosta; Marianne Cottagnoud; Lukas Flatz; Felix Kühn; Hans-Peter Müller; Armin Stucki
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Authors:  Molly E Steed; Brian J Werth; Cortney E Ireland; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.